These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

66 related items for PubMed ID: 2683189

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2. Results of EMATAP: a double-blind placebo-controlled multicentre trial of ticlopidine in patients with peripheral arterial disease.
    Blanchard J, Carreras LO, Kindermans M.
    Nouv Rev Fr Hematol (1978); 1994; 35(6):523-8. PubMed ID: 8152898
    [Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4. A double-blind, placebo-controlled multicentre trial of ticlopidine in patients with peripheral arterial disease in Argentina. Design, organization and general characteristics of patients at entry. The EMATAP Group.
    Blanchard JF, Carreras LO.
    Nouv Rev Fr Hematol (1978); 1992; 34(2):149-53. PubMed ID: 1502021
    [Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6. [Role of antiaggregants in the treatment of arterial diseases of the lower limbs].
    Boissel JP.
    Arch Mal Coeur Vaiss; 1991 Nov; 84(11 Suppl):1721-4. PubMed ID: 1837446
    [Abstract] [Full Text] [Related]

  • 7. The Clopidogrel in Unstable angina to prevent Recurrent Events (CURE) trial programme; rationale, design and baseline characteristics including a meta-analysis of the effects of thienopyridines in vascular disease.
    Mehta SR, Yusuf S, Clopidogrel in Unstable angina to prevent Recurrent Events (CURE) Study Investigators.
    Eur Heart J; 2000 Dec; 21(24):2033-41. PubMed ID: 11102254
    [Abstract] [Full Text] [Related]

  • 8. Antithrombotic drugs in the primary medical management of intermittent claudication: a meta-analysis.
    Girolami B, Bernardi E, Prins MH, ten Cate JW, Prandoni P, Hettiarachchi R, Marras E, Stefani PM, Girolami A, Büller HR.
    Thromb Haemost; 1999 May; 81(5):715-22. PubMed ID: 10365743
    [Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11. Safety and efficacy evaluation of clopidogrel compared to ticlopidine after stent implantation: an updated meta-analysis.
    Casella G, Ottani F, Pavesi PC, Sangiorgio P, Rubboli A, Galvani M, Fontanelli A, Bracchetti D.
    Ital Heart J; 2003 Oct; 4(10):677-84. PubMed ID: 14664280
    [Abstract] [Full Text] [Related]

  • 12. Clopidogrel and [symbol: see text] ticlopidine--improvements on aspirin?
    Drug Ther Bull; 1999 Aug; 37(8):59-61. PubMed ID: 10696686
    [Abstract] [Full Text] [Related]

  • 13. The HOPE Study (Heart Outcomes Prevention Evaluation).
    Sleight P.
    J Renin Angiotensin Aldosterone Syst; 2000 Mar; 1(1):18-20. PubMed ID: 11967789
    [Abstract] [Full Text] [Related]

  • 14. Tissue angiotensin-converting enzyme inhibitors for the prevention of cardiovascular disease in patients with diabetes mellitus without left ventricular systolic dysfunction or clinical evidence of heart failure: a pooled meta-analysis of randomized placebo-controlled clinical trials.
    Saha SA, Molnar J, Arora RR.
    Diabetes Obes Metab; 2008 Jan; 10(1):41-52. PubMed ID: 18095949
    [Abstract] [Full Text] [Related]

  • 15. Clopidogrel added to aspirin versus aspirin alone in secondary prevention and high-risk primary prevention: rationale and design of the Clopidogrel for High Atherothrombotic Risk and Ischemic Stabilization, Management, and Avoidance (CHARISMA) trial.
    Bhatt DL, Topol EJ, Clopidogrel for High Atherothrombotic Risk and Ischemic Stabilization, Management, and Avoidance Executive Committee.
    Am Heart J; 2004 Aug; 148(2):263-8. PubMed ID: 15308995
    [Abstract] [Full Text] [Related]

  • 16. Management of agitation, aggression, and psychosis associated with dementia: a pooled analysis including three randomized, placebo-controlled double-blind trials in nursing home residents treated with risperidone.
    De Deyn PP, Katz IR, Brodaty H, Lyons B, Greenspan A, Burns A.
    Clin Neurol Neurosurg; 2005 Oct; 107(6):497-508. PubMed ID: 15922506
    [Abstract] [Full Text] [Related]

  • 17. Letter by De Backer et al regarding article, "Oral buflomedil in the prevention of cardiovascular events in patients with peripheral arterial obstructive disease: a randomized, placebo-controlled, 4-year study".
    De Backer TL, Vander Stichele RH, Van Bortel LM.
    Circulation; 2008 Sep 02; 118(10):e151. PubMed ID: 18765384
    [No Abstract] [Full Text] [Related]

  • 18. Prasugrel: new drug. After angioplasty and stenting: continue to use aspirin + clopidogrel.
    Prescrire Int; 2009 Oct 02; 18(103):193-5. PubMed ID: 19877380
    [Abstract] [Full Text] [Related]

  • 19. Effects of fosinopril and pravastatin on cardiovascular events in subjects with microalbuminuria.
    Asselbergs FW, Diercks GF, Hillege HL, van Boven AJ, Janssen WM, Voors AA, de Zeeuw D, de Jong PE, van Veldhuisen DJ, van Gilst WH, Prevention of Renal and Vascular Endstage Disease Intervention Trial (PREVEND IT) Investigators.
    Circulation; 2004 Nov 02; 110(18):2809-16. PubMed ID: 15492322
    [Abstract] [Full Text] [Related]

  • 20. Variability in responsiveness to clopidogrel in patients with intermittent claudication.
    Cassar K, Bachoo P, Ford I, Greaves M, Brittenden J.
    Eur J Vasc Endovasc Surg; 2006 Jul 02; 32(1):71-5. PubMed ID: 16549375
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 4.